IAMOG
XLO icon

Investors Asset Management of Georgia’s Xilio Therapeutics XLO Stock Holding History

Investors Asset Management of Georgia’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-714
Closed -$6.4K – 190
2025
Q4 		$6.4K Hold
714
– – ﹤0.01% 184
2025
Q3 		$8.43K Hold
714
– – ﹤0.01% 179
2025
Q2 		$6.8K Hold
714
– – ﹤0.01% 169
2025
Q1 		$7.24K Buy
+714
New +$8.97K ﹤0.01% 161

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Investors Asset Management of Georgia's XLO Position: Q1 2026 in Review

Investors Asset Management of Georgia sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 714 shares — an estimated $6.4K sold.

Investors Asset Management of Georgia first reported a position in XLO in Q1 2025 and held it in 4 quarters. The position peaked at $8.43K in Q3 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Investors Asset Management of Georgia reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 714 Xilio Therapeutics shares in Q1 2026, an estimated $6.4K.
  • Investors Asset Management of Georgia first reported a position in Xilio Therapeutics in Q1 2025 and held it in 4 quarters.
  • Investors Asset Management of Georgia's Xilio Therapeutics position peaked at $8.43K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Investors Asset Management of Georgia's 13F filing for Q1 2026, filed 27 Apr 2026.